<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics	</title>
	<atom:link href="https://9krapalm.com/innovent-announces-results-of-a-phase-2-study-of-picankibart-anti-il-23p19-antibody-in-plaque-psoriasis-showing-efficacy-in-patients-with-prior-inadequate-response-to-il-17-biologics/feed/" rel="self" type="application/rss+xml" />
	<link>https://9krapalm.com/innovent-announces-results-of-a-phase-2-study-of-picankibart-anti-il-23p19-antibody-in-plaque-psoriasis-showing-efficacy-in-patients-with-prior-inadequate-response-to-il-17-biologics/</link>
	<description>เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm</description>
	<lastBuildDate>Tue, 29 Oct 2024 00:49:31 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>
</channel>
</rss>
